EUVIMEDEUVIMED entdecken
Open Access

Intravitreal Delivery of PEGylated-ECO Plasmid DNA Nanoparticles for Gene Therapy of Stargardt Disease

Da Sun, Wenyu Sun, Song-Qi Gao, Jonathan Lehrer, Hong Wang, Ryan Hall, Zheng-Rong Lu

Pharmaceutical Research · 2024

DOI: 10.1007/s11095-024-03679-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Da Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, United States. Hauptthemen laut MEDLINE: Retina, Nanoparticles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Current gene therapy of inherited retinal diseases is achieved mainly by subretinal injection, which is invasive with severe adverse effects. Intravitreal injection is a minimally invasive alternative for gene therapy of inherited retinal diseases. This work explores the efficacy of intravitreal delivery of PEGylated ECO (a multifunctional pH-sensitive amphiphilic amino lipid) plasmid DNA (pGRK1-ABCA4-S/MAR) nanoparticles (PEG-ELNP) for gene therapy of Stargardt disease. METHODS: Pigmented Abca4-/- knockout mice received 1 µL of PEG-ELNP solution (200 ng/uL, pDNA concentration) by intravitreal injections at an interval of 1.5 months. The expression of ABCA4 in the retina was determined by RT-PCR and immunohistochemistry at 6 months after the second injection. A2E levels in the treated eyes and untreated controls were determined by HPLC. The safety of treatment was monitored by scanning laser ophthalmoscopy and electroretinogram (ERG). RESULTS: PEG-ELNP resulted in significant ABCA4 expression at both mRNA level and protein level at]6 months after 2 intravitreal injections, and a 40% A2E accumulation reduction compared with non-treated controls. The PEG-ELNP also demonstrated excellent safety as shown by scanning laser ophthalmoscopy, and the eye function evaluation from electroretinogram. CONCLUSIONS: Intravitreal delivery of the PEG-ELNP of pGRK1-ABCA4-S/MAR is a promising approach for gene therapy of Stargardt Disease, which can also be a delivery platform for gene therapy of other inherited retinal diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RetinaNanoparticlesMiceAnimalsStargardt DiseaseGenetic TherapyPlasmidsDNAMice, KnockoutPolyethylene GlycolsIntravitreal InjectionsATP-Binding Cassette Transporters

Stichwörter der Autor:innen

ECOgene therapyintravitreal deliverylipid nanoparticlesstargardt disease

Substanzen

DNAPolyethylene GlycolsAbca4 protein, mouseATP-Binding Cassette Transporters

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, United States.
  • Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, United States. zxl125@case.edu.

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIH
  • Harrington Discovery Institute, University Hospitals

Zitieren

APA

Sun, D., Sun, W., Gao, S. Q., Lehrer, J., Wang, H., Hall, R., & Lu, Z. R. (2024). Intravitreal Delivery of PEGylated-ECO Plasmid DNA Nanoparticles for Gene Therapy of Stargardt Disease. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03679-1

Vancouver

Sun D, Sun W, Gao SQ, Lehrer J, Wang H, Hall R, et al. Intravitreal Delivery of PEGylated-ECO Plasmid DNA Nanoparticles for Gene Therapy of Stargardt Disease. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03679-1

BibTeX
@article{Sun2024,
  author = {Sun, Da and Sun, Wenyu and Gao, Song-Qi and Lehrer, Jonathan and Wang, Hong and Hall, Ryan and Lu, Zheng-Rong},
  title = {Intravitreal Delivery of PEGylated-ECO Plasmid DNA Nanoparticles for Gene Therapy of Stargardt Disease},
  journal = {Pharmaceutical Research},
  year = {2024},
  doi = {10.1007/s11095-024-03679-1}
}
Kostenlos starten →